Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Robert B Chao, MD doctorRBC
3 years 1 month ago
NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy.
*Numerical reduction in syndesmophytes 11% vs. 25%
Abs#0546
@RheumNow #ACR22
#ACRBest https://t.co/pG5F3xdsh9
Dr. Rachel Tate uptoTate
3 years 1 month ago
Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip
David Liew drdavidliew
3 years 1 month ago
In GCA, do you give pulse IV methylpred to patients with visual symptoms (instead of ongoing oral pred)? #ACR22 @RheumNow
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
#Abstr 0545 GO-BACK Trial
Continue vs Withdrawal of GOL in nr-axSpA with inactive disease
- Full tx withdrawal associated w/ dx flare
- Re-treatment -->rapid clinical response after flare
- qMonthly tx --> higher rates of disease activity improvement
@RheumNow #ACR22 https://t.co/Z3bhA9D4RQ
sheila RHEUMarampa
3 years 1 month ago
P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares
📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL
📌Non-adj: antidsDNA+, antiSm+ addt'l predictors
🧐p alb & antiSm+ potential predictors?
#ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe
Dr. Rachel Tate uptoTate
3 years 1 month ago
Majority of pts withdrawn from IXE to PBO recaptured at least LDA & over half met ID w/ IXE retreatment. This may help us clinically with pts who have treatment interruptions. Abs 0427 #ACR22 @RheumNow https://t.co/m4c3P8l25m https://t.co/iQshG1oq2Y
sheila RHEUMarampa
3 years 1 month ago
The CONSUL trial by Dr Proft et al. compared impact of CEL+GOL vs. GOL alone on radiographic spinal progression in AS showed no significant difference bet. the 2 grps in mSASSS change after 108 wks.
Risk stratify pts who will benefit from tx
#ACR22 @RheumNow ABST#0546 #ACRBest https://t.co/jWwX7w85ur
Dr. Rachel Tate uptoTate
3 years 1 month ago
Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt
Kim Lauper ☮️🕊️ k_lauper
3 years 1 month ago
Presenting our last (virtual) #JAKpot poster at #ACR22 1-3 pm ET (7-10 CET) in the RA treatment session.
Does anyone know what we will are supposed to do? Stay in front of our computer for 2 hours? @rheum_cat @ProftDr @DrMiniDey @EMEUNET @KragstrupTW https://t.co/uCNMezmJ4V
😷Dr. Rebecca Tuetken BeckySueToo
3 years 1 month ago
#ACR22 KNOWLEDGE bowl Dr. Namrata Singh, a judge this year, lead the U Iowa team in their bowl championship 3-peet, 2014, ‘15 & ‘16.
Deb Constien debconstien
3 years 1 month ago
Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22 @IFAiArthritis https://t.co/ChET0ckm0X
David Liew drdavidliew
3 years 1 month ago
@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results.
It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril.
ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF
sheila RHEUMarampa
3 years 1 month ago
How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines:
💉Pre-vax:
💊csDMARDs - hold time 4 wks
💊bDMARDs -hold time of one dosing interval
💉Post-vax: hold DMARDs for 4 wks
#ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC
Dr. Rachel Tate uptoTate
3 years 1 month ago
#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ
Poster Hall